CNS Pharmaceuticals, Inc. (CNSP) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 17, 2025, reports a material modification to the rights of security holders for CNS Pharmaceuticals, Inc., a Nevada corporation. The primary event is the implementation of a one-for-twelve (1-for-12) reverse stock split of the Company's common stock, which became effective at 12:01 a.m. Eastern Time on July 22, 2025.
Key Financial Metrics and Capital Structure
The filing provides historical loss data adjusted for the reverse split but does not contain current period revenue, cash flow, or liquidity metrics.
- Net Loss (12 Months Ended Dec 31, 2024): $14,857,801 (unchanged by split).
- Net Loss (12 Months Ended Dec 31, 2023): $18,851,226 (unchanged by split).
- Net Loss (3 Months Ended Mar 31, 2025): $4,301,320 (unchanged by split).
- Post-Split Shares Outstanding (as of July 22, 2025): Approximately 529,829 shares.
- Authorized Common Stock: Reduced from 300,000,000 to 25,000,000 shares.
- Authorized Preferred Stock: Reduced from 5,000,000 to 416,667 shares.
- New CUSIP Number: 18978H508.
Material Changes Versus Prior Period
The filing details the mechanical impact of the reverse stock split on historical per-share metrics. While total net losses remain constant, the loss per share and weighted average shares outstanding have been restated on a post-split basis.
- Loss Per Share Adjustment (12 Months Ended Dec 31, 2024): Restated from a pre-split basic loss of $(38.87) to a post-split basic loss of $(466.43).
- Loss Per Share Adjustment (3 Months Ended Mar 31, 2025): Restated from a pre-split basic loss of $(1.58) to a post-split basic loss of $(18.93).
- Share Count Reduction: The number of outstanding shares was reduced by a factor of 12.
Guidance, Outlook, and Unusual Items
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard implications of a reverse split.
- Fractional Shares: No fractional shares will be issued. Stockholders entitled to fractional shares will receive a cash payment in lieu thereof.
- Derivatives: All outstanding warrants and other derivatives automatically adjust per their terms to reflect the reverse split.
- Approval: The Board of Directors effected the split without stockholder approval pursuant to Nevada Revised Statutes 78.207.
Investor Verification Checklist
- Verify the new CUSIP number (18978H508) for trading purposes.
- Confirm the cash settlement amount for any fractional shares held prior to the split.
- Review the adjusted terms of any outstanding warrants or derivative securities held.
- Monitor the post-split share price to ensure it reflects the 1-for-12 ratio adjustment.
- Note that the filing does not provide updated liquidity or cash position data; refer to the most recent 10-Q or 10-K for current financial health.